Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced the company will present modeling data evaluati...
Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD) annual con...
AstraZeneca will share new data across its Vaccines & Immune Therapies portfolio at the 13th annual IDWeek in Los Angeles, California, from 16-19 ...
Avirmax Biopharma Inc. (ABI) team will attend AAO 2024, the American Academy of Ophthalmology's annual meeting in Chicago, October 17-21, 20...
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage oncology company pioneering the development of site-specific and novel-format antibody-drug conjug...
In an exclusive statement released through Guggenheim Securities, LLC, former Pfizer CEO Ian Read and former CFO Frank D’Amelio addressed growing s...
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), a pioneering life sciences technology firm that offers critical automation solut...
First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigim...
One of the notable achievements in fiscal 2023 was Catalent's robust efforts to mitigate its environmental impact and combat climate ...
Exscientia plc (Nasdaq: EXAI), a frontrunner in AI-driven precision medicine, has officially announced a significant leadership adjustment and the submissi...
In a landmark move within the life sciences sector, Novo Holdings has announced its acquisition of Catalent, Inc. in an all-cash transaction valued at $16....
From The BioPharma BoardRoom Lens The news of Tomas Blomquist stepping down from his role as CEO & President of Biotage AB carries sev...
The company is set to introduce multi-omics capabilities on the AVITI platform, along with enhancements to the first commercial Q50 kit and a host of workf...
QIAGEN announced a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repurchase tha...
© 2025 Biopharma Boardroom. All Rights Reserved.
